Brokerages expect Innospec Inc. (NASDAQ:IOSP) to post earnings per share (EPS) of $1.35 for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Innospec’s earnings. Innospec reported earnings per share of $1.47 during the same quarter last year, which indicates a negative year over year growth rate of 8.2%. The firm is scheduled to announce its next earnings results on Tuesday, February 12th.

On average, analysts expect that Innospec will report full-year earnings of $4.55 per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post earnings of $4.75 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Innospec.

Innospec (NASDAQ:IOSP) last released its quarterly earnings results on Tuesday, November 6th. The specialty chemicals company reported $1.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.14. Innospec had a return on equity of 14.02% and a net margin of 4.17%. The company had revenue of $363.10 million for the quarter, compared to analyst estimates of $362.50 million. During the same period in the previous year, the company posted $1.00 earnings per share. The firm’s revenue was up 9.2% on a year-over-year basis.

Several equities research analysts recently weighed in on IOSP shares. Zacks Investment Research upgraded Innospec from a “sell” rating to a “hold” rating in a research report on Wednesday, September 26th. KeyCorp dropped their price target on Innospec from $86.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, November 16th. ValuEngine upgraded Innospec from a “hold” rating to a “buy” rating in a research report on Wednesday, November 7th. Finally, BidaskClub raised Innospec from a “hold” rating to a “buy” rating in a report on Tuesday, November 20th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.50.

Shares of NASDAQ IOSP traded down $0.78 during mid-day trading on Friday, hitting $66.08. 75,550 shares of the stock traded hands, compared to its average volume of 70,301. The company has a quick ratio of 1.37, a current ratio of 2.27 and a debt-to-equity ratio of 0.25. Innospec has a 52 week low of $62.13 and a 52 week high of $83.20. The firm has a market capitalization of $1.63 billion, a PE ratio of 14.18 and a beta of 1.11.

The business also recently announced a semiannual dividend, which was paid on Thursday, November 29th. Shareholders of record on Monday, November 19th were issued a $0.45 dividend. This represents a yield of 1.18%. The ex-dividend date of this dividend was Friday, November 16th. Innospec’s dividend payout ratio (DPR) is 19.31%.

Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can boosted its holdings in Innospec by 2,016.9% in the third quarter. Bank of Montreal Can now owns 21,677 shares of the specialty chemicals company’s stock worth $1,663,000 after acquiring an additional 20,653 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Innospec during the second quarter valued at $490,000. Wasatch Advisors Inc. lifted its holdings in shares of Innospec by 13.0% during the third quarter. Wasatch Advisors Inc. now owns 258,283 shares of the specialty chemicals company’s stock valued at $19,823,000 after purchasing an additional 29,619 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Innospec by 5.9% during the third quarter. Wells Fargo & Company MN now owns 1,162,551 shares of the specialty chemicals company’s stock valued at $89,226,000 after purchasing an additional 64,390 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Innospec by 327.5% during the second quarter. Russell Investments Group Ltd. now owns 20,992 shares of the specialty chemicals company’s stock valued at $1,608,000 after purchasing an additional 16,082 shares in the last quarter. 93.69% of the stock is currently owned by institutional investors and hedge funds.

About Innospec

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.

Further Reading: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on Innospec (IOSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.